Breadth of Anti-merozoite Antibody Responses is Associated with the Genetic Diversity of Asymptomatic Plasmodium Falciparum Infections and Protection Against Clinical Malaria

Overview

Journal Clin Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2013 Aug 29

PMID 23983244

Citations 44

Authors

Josea Rono

Faith H A Osier

Daniel Olsson

Scott Montgomery

Leah Mhoja

Ingegerd Rooth

Kevin Marsh

Anna Farnert

Affiliations

Soon will be listed here.

Abstract

Background: Elucidating the mechanisms of naturally acquired immunity to Plasmodium falciparum infections would be highly valuable for malaria vaccine development. Asymptomatic multiclonal infections have been shown to predict protection from clinical malaria in a transmission-dependent manner, but the mechanisms underlying this are unclear. We assessed the breadth of antibody responses to several vaccine candidate merozoite antigens in relation to the infecting parasite population and clinical immunity.

Methods: In a cohort study in Tanzania, 320 children aged 1-16 years who were asymptomatic at baseline were included. We genotyped P. falciparum infections by targeting the msp2 gene using polymerase chain reaction and capillary electrophoresis and measured antibodies to 7 merozoite antigens using a multiplex assay. We assessed the correlation between the number of clones and the breadth of the antibody response, and examined their effects on the risk of malaria during 40 weeks of follow-up using age-adjusted multivariate regression models.

Results: The antibody breadth was positively correlated with the number of clones (RR [risk ratio], 1.63; 95% confidence interval [CI], 1.32-2.02). Multiclonal infections were associated with a nonsignificant reduction in the risk of malaria in the absence of antibodies (RR, 0.83; 95% CI, .29-2.34). The breadth of the antibody response was significantly associated with a reduced risk of malaria in the absence of infections (RR, 0.25; 95% CI, .09-.66). In combination, these factors were associated with a lower risk of malaria than they were individually (RR, 0.14; 95% CI, .04-.48).

Conclusions: These data suggest that malaria vaccines mimicking naturally acquired immunity should ideally induce antibody responses that can be boosted by natural infections.

Citing Articles

Naturally acquired IgG responses to do not target the conserved termini of the malaria vaccine candidate Merozoite Surface Protein 2.

Zerebinski J, Margerie L, Han N, Moll M, Ritvos M, Jahnmatz P Front Immunol. 2024; 15:1501700.

PMID: 39717775 PMC: 11663719. DOI: 10.3389/fimmu.2024.1501700.

Breadth of Fc-mediated effector function correlates with clinical immunity following human malaria challenge.

Nkumama I, Ogwang R, Odera D, Musasia F, Mwai K, Nyamako L Immunity. 2024; 57(6):1215-1224.e6.

PMID: 38788711 PMC: 7616646. DOI: 10.1016/j.immuni.2024.05.001.

Distinct transcriptomic signatures define febrile malaria depending on initial infective states, asymptomatic or uninfected.

Kimenyi K, Akinyi M, Mwikali K, Gilmore T, Mwangi S, Omer E BMC Infect Dis. 2024; 24(1):140.

PMID: 38287287 PMC: 10823747. DOI: 10.1186/s12879-024-08973-2.

Background malaria incidence and parasitemia during the three-dose RTS,S/AS01 vaccination series do not reduce magnitude of antibody response nor efficacy against the first case of malaria.

Bell G, Gyaase S, Goel V, Adu B, Mensah B, Essone P BMC Infect Dis. 2023; 23(1):716.

PMID: 37872492 PMC: 10594884. DOI: 10.1186/s12879-023-08699-7.

High Prevalence of Polyclonal Infections and Association with Poor IgG Antibody Responses in a Hyper-Endemic Area in Cameroon.

Biabi M, Fogang B, Essangui E, Maloba F, Donkeu C, Keumoe R Trop Med Infect Dis. 2023; 8(8).

PMID: 37624328 PMC: 10459087. DOI: 10.3390/tropicalmed8080390.

References

Mackinnon M, Mwangi T, Snow R, Marsh K, Williams T . Heritability of malaria in Africa. PLoS Med. 2005; 2(12):e340. PMC: 1277928. DOI: 10.1371/journal.pmed.0020340. View

Burghaus P, Holder A . Expression of the 19-kilodalton carboxy-terminal fragment of the Plasmodium falciparum merozoite surface protein-1 in Escherichia coli as a correctly folded protein. Mol Biochem Parasitol. 1994; 64(1):165-9. DOI: 10.1016/0166-6851(94)90144-9. View

Felger I, Steiger S, Hatz C, Smith T, Beck H . Antigenic cross-reactivity between different alleles of the Plasmodium falciparum merozoite surface protein 2. Parasite Immunol. 2004; 25(11-12):531-43. DOI: 10.1111/j.0141-9838.2004.00664.x. View

Benichou J . A review of adjusted estimators of attributable risk. Stat Methods Med Res. 2001; 10(3):195-216. DOI: 10.1177/096228020101000303. View

Richards J, Stanisic D, Fowkes F, Tavul L, Dabod E, Thompson J . Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia. Clin Infect Dis. 2010; 51(8):e50-60. DOI: 10.1086/656413. View

Polley S, Conway D, Cavanagh D, McBride J, Lowe B, Williams T . High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya. Vaccine. 2005; 24(19):4233-46. DOI: 10.1016/j.vaccine.2005.06.030. View

Greenhouse B, Ho B, Hubbard A, Njama-Meya D, Narum D, Lanar D . Antibodies to Plasmodium falciparum antigens predict a higher risk of malaria but protection from symptoms once parasitemic. J Infect Dis. 2011; 204(1):19-26. PMC: 3105040. DOI: 10.1093/infdis/jir223. View

Smith T, Beck H, Kitua A, Mwankusye S, Felger I, Fraser-Hurt N . Age dependence of the multiplicity of Plasmodium falciparum infections and of other malariological indices in an area of high endemicity. Trans R Soc Trop Med Hyg. 1999; 93 Suppl 1:15-20. DOI: 10.1016/s0035-9203(99)90322-x. View

Taylor R, Smith D, Robinson V, McBride J, Riley E . Human antibody response to Plasmodium falciparum merozoite surface protein 2 is serogroup specific and predominantly of the immunoglobulin G3 subclass. Infect Immun. 1995; 63(11):4382-8. PMC: 173623. DOI: 10.1128/iai.63.11.4382-4388.1995. View

10.

Felger I, Smith T, Edoh D, Kitua A, Alonso P, Tanner M . Multiple Plasmodium falciparum infections in Tanzanian infants. Trans R Soc Trop Med Hyg. 1999; 93 Suppl 1:29-34. DOI: 10.1016/s0035-9203(99)90324-3. View

11.

Bereczky S, Liljander A, Rooth I, Faraja L, Granath F, Montgomery S . Multiclonal asymptomatic Plasmodium falciparum infections predict a reduced risk of malaria disease in a Tanzanian population. Microbes Infect. 2006; 9(1):103-10. DOI: 10.1016/j.micinf.2006.10.014. View

12.

Mueller I, Schoepflin S, Smith T, Benton K, Bretscher M, Lin E . Force of infection is key to understanding the epidemiology of Plasmodium falciparum malaria in Papua New Guinean children. Proc Natl Acad Sci U S A. 2012; 109(25):10030-5. PMC: 3382533. DOI: 10.1073/pnas.1200841109. View

13.

Liljander A, Wiklund L, Falk N, Kweku M, Martensson A, Felger I . Optimization and validation of multi-coloured capillary electrophoresis for genotyping of Plasmodium falciparum merozoite surface proteins (msp1 and 2). Malar J. 2009; 8:78. PMC: 2680902. DOI: 10.1186/1475-2875-8-78. View

14.

Murungi L, Kamuyu G, Lowe B, Bejon P, Theisen M, Kinyanjui S . A threshold concentration of anti-merozoite antibodies is required for protection from clinical episodes of malaria. Vaccine. 2013; 31(37):3936-42. PMC: 3763364. DOI: 10.1016/j.vaccine.2013.06.042. View

15.

Ranford-Cartwright L, Balfe P, Carter R, Walliker D . Frequency of cross-fertilization in the human malaria parasite Plasmodium falciparum. Parasitology. 1993; 107 ( Pt 1):11-8. DOI: 10.1017/s003118200007935x. View

16.

Smith T, Felger I, Tanner M, Beck H . Premunition in Plasmodium falciparum infection: insights from the epidemiology of multiple infections. Trans R Soc Trop Med Hyg. 1999; 93 Suppl 1:59-64. DOI: 10.1016/s0035-9203(99)90329-2. View

17.

Polley S, Tetteh K, Lloyd J, Akpogheneta O, Greenwood B, Bojang K . Plasmodium falciparum merozoite surface protein 3 is a target of allele-specific immunity and alleles are maintained by natural selection. J Infect Dis. 2006; 195(2):279-87. DOI: 10.1086/509806. View

18.

Ntoumi F, Contamin H, Rogier C, Bonnefoy S, Trape J, Mercereau-Puijalon O . Age-dependent carriage of multiple Plasmodium falciparum merozoite surface antigen-2 alleles in asymptomatic malaria infections. Am J Trop Med Hyg. 1995; 52(1):81-8. DOI: 10.4269/ajtmh.1995.52.81. View

19.

Mayor A, Saute F, Aponte J, Almeda J, Gomez-Olive F, Dgedge M . Plasmodium falciparum multiple infections in Mozambique, its relation to other malariological indices and to prospective risk of malaria morbidity. Trop Med Int Health. 2003; 8(1):3-11. DOI: 10.1046/j.1365-3156.2003.00968.x. View

20.

Liljander A, Chandramohan D, Kweku M, Olsson D, Montgomery S, Greenwood B . Influences of intermittent preventive treatment and persistent multiclonal Plasmodium falciparum infections on clinical malaria risk. PLoS One. 2010; 5(10):e13649. PMC: 2965101. DOI: 10.1371/journal.pone.0013649. View